MDM2 and neoplasm: The more recent development of RG7388 (Idasanutlin), a second-generation MDM2 inhibitor with greater potency, selectivity, bioavailability and effective p53-activating ability leading to the p53-mediated induction of tumour cell apoptosis, is promising for cancers, including GBM [18,19].